Perimenopause, Menopause and ADHD: Why It Often Gets Worse

A common pattern in adult ADHD clinics: women in their forties and fifties who have managed for decades with workarounds find that their ADHD symptoms intensify substantially around perimenopause and menopause. For some, this is when they reach an ADHD assessment for the first time. The biology is well established at the level of oestrogen and dopamine signalling, and the implications for treatment are now being recognised in clinical practice. This article covers what the evidence shows, what is going on biologically, and how UK treatment is shaped.

What perimenopause and menopause are

Perimenopause is the transitional period in the years before menopause, during which ovarian hormone production becomes increasingly irregular. Oestrogen levels fluctuate widely and then decline. Most women experience perimenopause across several years before periods stop, typically beginning in the early to mid-forties, although it can start earlier or later.

Menopause is reached when periods have stopped for twelve consecutive months. The average age in the UK is around 51. Post-menopause, oestrogen levels remain low. NICE NG23 sets out the UK clinical approach to identification and management ^[1].

Why ADHD symptoms intensify

The mechanism involves oestrogen and dopamine. Oestrogen modulates dopamine signalling in the prefrontal cortex and striatum, the same circuits most affected in ADHD. As oestrogen declines through perimenopause and into menopause, dopamine signalling is less supported, and the underlying ADHD difficulties become harder to compensate for ^{[4, 5, 6]}.

The clinical pattern that follows is recognisable:

• A clear worsening of attention, working memory, and task initiation, often described as "brain fog"
• Worsened emotional regulation and irritability
• Worsened sleep, often layered on top of menopausal sleep disturbance from hot flushes and night sweats
• A sense of "no longer being able to do what I used to be able to do" in work and family life
• Workarounds that have served for decades stop being sufficient
• For some women, the period of perimenopause is when ADHD becomes recognisable for the first time

For women already diagnosed with ADHD, the perimenopause and menopause years often require medication adjustments and renewed structural support. For undiagnosed women, this is when many reach an ADHD assessment for the first time, often after the menopausal "brain fog" has been investigated and the underlying ADHD has emerged underneath.

What the evidence shows

The dedicated research on ADHD in perimenopause and menopause is still emerging, but several anchor points are reasonably solid:

• Oestrogen's modulation of dopamine signalling is well established at the basic science level ^[4]
• Quinn and Madhoo's 2014 review and subsequent clinical literature emphasise the cyclical and stage-of-life variation in ADHD symptoms in women, with perimenopause as a particular risk point ^[5]
• The 2021 Antoniou et al. review summarised the literature on ADHD across the female lifespan and highlighted the perimenopause and menopause years as a recognised but under-researched period of symptom intensification ^[6]
• Clinical experience across UK ADHD services, both NHS and private, has converged on perimenopause as one of the most common life-stage triggers for late ADHD diagnosis in women

The evidence base is strongest for the biological mechanism (oestrogen-dopamine) and for clinical observation. Large randomised controlled trials of hormonal interventions specifically for ADHD symptoms in perimenopause are scarce.

How treatment is shaped

Several practical principles apply when ADHD intensifies around perimenopause or menopause ^{[1, 2, 6]}:

Address ADHD specifically

For women already diagnosed, a review of ADHD medication is often appropriate. Some women need a dose adjustment as oestrogen declines; others move from one medication to another; some need additional structural support that was not previously necessary. The detail is part of the standard ADHD prescribing pathway.

For women presenting with ADHD-type difficulties for the first time in perimenopause, ADHD assessment is appropriate where the childhood history shows ADHD-type features that have been worked around for decades. The "menopause brain fog" picture in someone whose childhood school reports describe distractibility, disorganisation or daydreaming is often ADHD becoming visible under reduced compensation.

Consider hormone replacement therapy (HRT) where appropriate

NICE NG23 sets out the UK approach to HRT in perimenopause and menopause ^[1]. HRT is not an ADHD treatment, but where perimenopausal symptoms (hot flushes, night sweats, mood and cognitive symptoms) are significant, HRT may be appropriate on the standard menopause indications. Some women find that HRT improves the cognitive and emotional symptoms in a way that supports overall function alongside ADHD treatment. The British Menopause Society has UK-specific resources for clinicians and patients ^[3].

The choice of HRT formulation is individual and is a GP or specialist conversation. Not every woman needs or wants HRT; the decision is shaped by her specific symptoms, her medical history and her preferences.

ADHD medication and HRT together

Concurrent use of ADHD medication and HRT is clinically reasonable for most women. Specific interactions are checked by the prescriber. There is no general contraindication.

Sleep, mood and the wider picture

Perimenopause and menopause often bring sleep disturbance, mood changes, and reduced physical and cognitive resilience independent of ADHD. Treating each strand (HRT or non-hormonal options for menopausal symptoms, sleep support, mood treatment where indicated, ADHD treatment) often produces a better outcome than focusing on one alone.

The 30,000-foot picture

For many women in this stage of life, the combination of ADHD becoming more visible, perimenopausal change, and the accumulated stress of midlife responsibilities (caring for older parents, supporting teenage or young adult children, demanding work) produces a particularly difficult period. Recognising the ADHD strand, where it is present, often opens up a meaningful improvement that would not otherwise be available. ADHD in women: missed, misread, misunderstood covers the broader picture.

When the perimenopause pattern is the leading edge

A common adult presentation: a woman in her mid-forties to early fifties whose lifelong workarounds have stopped working, who has been investigated for menopausal cognitive symptoms, who has been treated for anxiety or depression with partial response, and whose childhood history shows clear ADHD-type features. The eventual ADHD assessment confirms the underlying condition. NeuroFX offers private adult ADHD assessment for women with the perimenopause and menopause picture explicitly considered.

What this means in practice

• ADHD symptoms commonly intensify during perimenopause and menopause because oestrogen modulates dopamine signalling.
• For women already diagnosed with ADHD, medication adjustments and renewed structural support are often appropriate.
• For undiagnosed women, this stage of life is one of the most common times for ADHD to become recognisable for the first time.
• HRT under NICE NG23 is not an ADHD treatment but can support overall function where menopausal symptoms are significant. The decision is individual.
• The combination of perimenopausal change, accumulated midlife stress, and previously hidden ADHD often produces a particularly difficult period that responds well to recognising the ADHD strand.

When to speak to a professional

Speak to your GP if perimenopausal symptoms (including cognitive and emotional symptoms) are significantly affecting daily function, particularly if ADHD-type difficulties have been present since childhood. NICE NG23 and the British Menopause Society guide the UK menopause pathway. NeuroFX offers private ADHD assessment for adults with the women's pathway considering the perimenopause and menopause context from the start. Seek urgent help via 111, 999 or A&E for any acute mental health crisis.

Sources

1. NICE. Menopause: identification and management. NG23. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng23
2. NICE. Attention deficit hyperactivity disorder: diagnosis and management. NG87. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87
3. British Menopause Society. Tools for clinicians. https://thebms.org.uk/
4. Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews. 2021;128:789-818.
5. Quinn PO, Madhoo M. A review of attention-deficit/hyperactivity disorder in women and girls: uncovering this hidden diagnosis. Primary Care Companion for CNS Disorders. 2014;16(3):PCC.13r01596.
6. Antoniou E, Rigas N, Orovou E, Papatrechas A, Sarella A. ADHD Symptoms in Females of Childhood, Adolescent, Reproductive and Menopausal Period. Materia Socio-Medica. 2021;33(2):114-118.